Cerebrospinal fluid β‐amyloid and phospho‐tau biomarker interactions affecting brain structure in preclinical Alzheimer disease
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Objective: To assess the relationships between core cerebrospinal fluid (CSF) biomarkers and cortical thickness (CTh) in preclinical Alzheimer disease (AD). Methods: In this cross‐sectional study, normal controls (n = 145) from the Alzheimer's Disease Neuroimaging Initiative underwent structural 3T magnetic resonance imaging (MRI) and lumbar puncture. CSF β‐amyloid 1–42 (Aβ) and phospho‐tau 181p (p‐tau) levels were measured by Luminex assays. Samples were dichotomized using published cutoffs (Aβ+/Aβ− and p‐tau+/ptau−). CTh was measured by Freesurfer. CTh difference maps were derived from interaction and correlation analyses. Clusters from the interaction analysis were isolated to analyze the directionality of the interaction by analysis of covariance. Results: We found a significant biomarker interaction between CSF Aβ and CSF p‐tau levels affecting brain structure. Cortical atrophy only occurs in subjects with both Aβ+ and p‐tau+. The stratified correlation analyses showed that the relationship between p‐tau and CTh is modified by Aβ status and the relationship between Aβ and CTh is modified by p‐tau status. p‐Tau–dependent thinning was found in different cortical regions in Aβ+ subjects but not in Aβ− subjects. Cortical thickening was related to decreasing CSF Aβ values in the absence of abnormal p‐tau, but no correlations were found in p‐tau+ subjects. Interpretation: Our data suggest that interactions between biomarkers in AD result in a 2‐phase phenomenon of pathological cortical thickening associated with low CSF Aβ, followed by atrophy once CSF p‐tau becomes abnormal. These interactions should be considered in clinical trials in preclinical AD, both when selecting patients and when using MRI as a surrogate marker of efficacy. Ann Neurol 2014;76:223–230
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“b-Amyloid1–42 (Ab) deposition is thought to be an early event, and the biomarkers related to brain amyloidosis are the first to become abnormal.(1,2) The long preclinical phase in AD is divided into 3 stages based on operational research criteria(1): asymptomatic cerebral amyloidosis (stage 1), stage 1 plus evidence o…”
BackgroundJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 1×
“Furthermore, the Ab accumulation can enhance tau pathology in transgenic mouse models.(29,30) In this respect, a very recent and elegant work in humans and mouse models shows that APP expression acts to potentiate and accelerate tau toxicity in driving lateral entorhinal cortex dysfunction.”
BackgroundDickerson, B. C., Bakkour, A., Salat, D. H., Feczko, E., Pacheco, J., Greve, D. N., Grodstein, F., Wright, C. I., Blacker, D., Rosas, H. D., et al. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn113 · Cited by 1,153
Cited by
Synergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Zetterberg, H., Skillbäck, T., Mattsson, N., Trojanowski, J. Q., Portelius, E., Shaw, L. M., Weiner, M. W., Blennow, K., & Initiative, F. T. A. D. N. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3037 · Cited by 487
Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
Kamatham, P. T., Shukla, R., Khatri, D. K., & Vora, L. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102481 · Cited by 371
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Morris, J. C., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.11.007 · Cited by 315
Cortical microstructural changes along the Alzheimer’s disease continuum
Montal, V., Vilaplana, E., Alcolea, D., Pegueroles, J., Pasternak, O., González‐Ortiz, S., Clarimón, J., Carmona‐Iragui, M., Illán‐Gala, I., Morenas‐Rodríguez, E., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.09.013 · Cited by 204
“Brain amyloidosis, in the absence of tau, would be related to pathologic cortical thickening, decreased MD, and decreased FW, which would be followed by atrophy, increased MD, and increased FW once tau markers become abnormal [4].”
BackgroundMethodSelf-citation
Metadata
- Authors
- Fortea, J., Vilaplana, E., Alcolea, D., Carmona‐Iragui, M., Sánchez‐Saudinos, M., Sala, I., Antón‐Aguirre, S., González, S., Medrano, S., Pegueroles, J., Morenas, E., Clarimón, J., Blesa, R., Lleó, A., & Initiative, F. T. A. D. N.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2014-06-13
- Volume
- 76
- Issue
- 2
- Pages
- 223-230
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1836749191
- Cited by
- 143
- References
- 24
- FWCI
- 7.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cerebrospinal fluid β‐amyloid and phospho‐tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. https://app.cochat.ai/papers/10.1002/ana.24186
- The paper
- Fortea, J., Vilaplana, E., Alcolea, D., Carmona‐Iragui, M., Sánchez‐Saudinos, M., Sala, I., Antón‐Aguirre, S., González, S., Medrano, S., Pegueroles, J., Morenas, E., Clarimón, J., Blesa, R., Lleó, A., & Initiative, F. T. A. D. N. (2014). Cerebrospinal fluid β‐amyloid and phospho‐tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. Annals of Neurology. https://doi.org/10.1002/ana.24186
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.